Companies /Consumer Defensive

Altria Group Inc

NYSE: MO Tobacco
$68.95
▼ $0.55 (−0.78%) today
Markets open · 4:10pm ET

Q4 2025 Earnings

Reported Jan 29, 2026, 7:04am ET · SEC source
$1.30
Miss −1.33%
EPS · est. $1.32
$5.8B
Beat +16.17%
Revenue · est. $5.0B
+17.3%
Beating market
MO vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
−6%−4%−2%0Jan 29Jan 30report 7:04am ETearnings−1.0%−3.5%
−6%−4%−2%0Jan 29Jan 30earnings−1.0%−3.5%
MO −3.5%S&P 500 −1.0%
−6%−4%−2%0Jan 29Jan 30report 7:04am ETearnings−1.9%−3.5%
−6%−4%−2%0Jan 29Jan 30earnings−1.9%−3.5%
MO −3.5%NASDAQ −1.9%
−3%0+3%Jan 28Feb 6report 7:04am ETearnings−2.2%+4.0%
−3%0+3%Jan 28Feb 6earnings−2.2%+4.0%
MO +4.0%S&P 500 −2.2%
−4%0+4%Jan 28Feb 6report 7:04am ETearnings−5.1%+4.0%
−4%0+4%Jan 28Feb 6earnings−5.1%+4.0%
MO +4.0%NASDAQ −5.1%
−5.34%
Day of report
+3.73%
Next session
+9.42%
One week
+15.28%
30 days

S&P 500 over the same 30 days: −1.98%.

Did MO Beat Earnings? Q4 2025 Results

Altria Group delivered a stronger-than-expected fourth quarter, posting adjusted diluted EPS of $1.30 against a consensus estimate of $1.2453 — a beat of 4.39% — while revenue of $5.85 billion topped expectations by 27.85% and climbed 29.4% year-over-year. The headline numbers, however, masked a more complicated picture: reported diluted EPS fell 63.1% to $0.66, dragged down by $1.30 billion in non-cash impairment charges tied to the NJOY e-vapor segment. The smokeable products business — Altria's core profit engine — saw Q4 net revenues slip 2.7% as domestic cigarette volumes fell 7.9%, with Marlboro's total category share retreating 1.5 points to 39.8% amid illicit e-vapor competition and discount-segment encroachment. Investors are weighing those structural pressures against the company's <a href="https://247wallst.com/investing/2026/02/10/altrias-6-5-dividend-has-been-raised-for-20-years-but-will-it-continue/">20-year dividend growth record</a> and a pending CEO transition. For 2026, Altria guided adjusted diluted EPS of $5.56 to $5.72, implying growth of 2.5% to 5.5%, with results expected to be back-half weighted.

Key Takeaways
  • Higher pricing in smokeable and oral tobacco segments partially offsetting volume declines
  • Fewer shares outstanding from $1 billion in share repurchases during 2025
  • Lower adjusted tax rate of 23.2% for full year 2025 vs. 24.2% prior year
  • Optimize & Accelerate initiative delivering cost savings
  • Equity income from ABI investment of $498 million for full year

“2025 was a year of continued momentum for Altria, marked by strong financial performance, strategic progress across our smoke-free portfolio, new relationships in support of our long-term growth goals and significant cash returns to shareholders. For the full year, we grew adjusted diluted earnings per share by 4.4% and returned $8 billion to shareholders through dividends and share repurchases combined.”

Altria CEO, on the earnings call

Forward Guidance & Outlook

Altria expects 2026 full-year adjusted diluted EPS of $5.56 to $5.72, representing growth of 2.5% to 5.5% from a 2025 base of $5.42. Growth is expected to be weighted to the second half of 2026, reflecting a progressive increase in cigarette import and export activity. The guidance contemplates planned investments to support contract manufacturing capabilities, limited impact on combustible and e-vapor product volumes from illicit enforcement efforts, and that NJOY ACE does not return to the marketplace in 2026. The 2026 adjusted effective tax rate is expected to be 22.5% to 23.5%, capital expenditures between $300 million and $375 million, and depreciation and amortization approximately $225 million.

MO YoY Financials

Q4 2025 vs Q4 2024 · SEC filings Q4 2024 Q4 2025
$0$2.0B$4.0B$6.0B$4.5B$5.8BRevenue$3.2B$3.6BGross Profit$1.8B$1.7BOperating Income$1.1B$1.1BNet Income
$0$2.0B$4.0B$6.0BRevenueGross ProfitOperating IncomeNet Income

MO Revenue by Segment

Smokeable Products$5.1B−2.7%
Oral Tobacco Products$706.0M+2.0%
E-Vapor Products$21.0M−4.5%

Figures from SEC filings and company reports. Not investment advice.